Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Clinical trial

Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer

ID
Name
P420_PARP
Description
Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.
Trial arms
Trial start
2019-11-01
Estimated PCD
2021-06-30
Trial end
2023-09-30
Status
Active (not recruiting)
Treatment
PARP inhibitor
use at any line of treatment in patients with advanced ovarian cancer
Arms:
One cohort
Size
150
Primary endpoint
Evaluation of Progression Free Survival
12/2022
Eligibility criteria
Inclusion Criteria: - women \>18 years old with advanced high grade ovarian cancer Exclusion Criteria: -
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'OTHER'}, 'enrollmentInfo': {'count': 150, 'type': 'ESTIMATED'}}
Updated at
2023-03-14

1 organization

1 product

1 indication

Organization
Hellenic Cooperative Oncology Group
Product
PARP inhibitor
Indication
Ovarian Cancer